

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): August 17, 2016**

---

**Inotek Pharmaceuticals Corporation**  
(Exact name of registrant as specified in its charter)

---

**DELAWARE**  
(State or other jurisdiction  
of incorporation)

**001-36829**  
(Commission  
File Number)

**04-3475813**  
(I.R.S. Employer  
Identification No.)

**91 Hartwell Avenue**  
**Lexington, MA**  
(Address of principal executive offices)

**02421**  
(Zip Code)

**Registrant's telephone number, including area code (781) 676-2100**

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**Item 5.02(d) Election of a New Director**

On August 17, 2016, the Board of Directors (the “Board”) of Inotek Pharmaceuticals Corporation (the “Company”) appointed Patrick Machado to the Board. Mr. Machado will serve as a Class III director of the Company, to hold office until the date of the annual meeting of stockholders next following the year ending December 31, 2016, or until his earlier death, resignation or removal. The Board has determined that Mr. Machado satisfies the definition of “independent” director, including without limitation the applicable requirements of the NASDAQ Listing Rules and the Securities Exchange Act of 1934, as amended.

Mr. Machado, age 52, has served as a member of the Board of Directors at Medivation, Inc. and Chimerix, Inc. since 2014 and as a member of the Board of Directors of Scynexis, Inc. since 2015. Mr. Machado co-founded Medivation, Inc. and served as its Chief Business Officer from December, 2009 to April, 2014 and its Chief Financial Officer from December, 2004 to April, 2014. Prior to working for Medivation, Inc., Mr. Machado held positions at Cytoc Corporation, Pro•Duct Health, Inc., Chiron Corporation and Morrison & Foerster LLP. Mr. Machado received his Bachelor of Science in Economics and Bachelor of Arts in German from Santa Clara University and his Juris Doctor from Harvard Law School.

Upon his election to the Board, Mr. Machado was granted an option to purchase 24,000 shares of the Company’s common stock at an exercise price of \$6.91 per share, which is equal to the fair market value of the Company’s common stock on the date of grant (the “Vesting Commencement Date”). Twenty-five percent of the shares shall vest on the one year anniversary of the Vesting Commencement Date and 1/36<sup>th</sup> of the remaining shares shall vest on each monthly anniversary thereafter, subject to Mr. Machado’s continued service on the Board.

As a non-employee director, Mr. Machado will receive compensation in the same manner as the Company’s other non-employee directors. Additionally, in connection with Mr. Machado’s appointment to the Board, the Company and Mr. Machado will enter into an indemnification agreement in substantially the same form that the Company has entered into with each of the Company’s existing directors. The form of such indemnification agreement was previously filed by the Company as an exhibit to its Registration Statement on Form S-1 (File No. 333-199859) filed with the SEC.

In connection with his election to the Board, Mr. Machado was also appointed to the Board’s Audit Committee. The Board has determined that Mr. Machado satisfies all applicable requirements to serve on such committee.

There are no arrangements or understandings between Mr. Machado and any other persons pursuant to which he was appointed as a member of the Board. There are no family relationships between Mr. Machado and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Mr. Machado and the Company.

A copy of the press release announcing Mr. Machado's appointment is furnished herewith as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

*(d) Exhibits.*

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated August 18, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 18, 2016

**INOTEK PHARMACEUTICALS CORPORATION**

By: /s/ Dale Ritter  
Dale Ritter  
Vice President — Finance

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated August 18, 2016



### **Inotek Pharmaceuticals Appoints Patrick Machado, JD, to Board of Directors**

**Lexington, MA** — August 18, 2016 — Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company” or “Inotek”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Patrick Machado, JD, has been appointed to its Board of Directors. Mr. Machado will serve on the Audit Committee.

Mr. Machado most recently served as Co-Founder, Chief Business Officer and Chief Financial Officer of Medivation, Inc. (NASDAQ: MDVN), a biopharmaceutical company, for 11 years. At Medivation, Mr. Machado led the company through a period of substantial financial and clinical growth while managing all business development, financial, operations and legal functions of the company. Mr. Machado’s affiliations prior to Medivation included Cytoc Health Corporation, ProDuct Health, Inc., and Chiron Corporation.

Mr. Machado earned a JD, *Cum Laude*, from Harvard Law School and a BA and BS, *Summa Cum Laude*, in German and Economics, respectively, from Santa Clara University. He currently serves as a member of the Board of Directors of Medivation, Inc., Chimerix, Inc. (NASDAQ: CMRX), and Scynexis, Inc. (NASDAQ: SCYX).

“I am delighted to welcome Pat to Inotek’s Board of Directors” said David P. Southwell, President and Chief Executive Officer. “Mr. Machado’s diverse and extensive experience guiding late-stage biopharmaceutical companies through all stages of growth will be very valuable to us, as we grow Inotek with the development of *trabodenoson*.”

“Inotek’s promising pipeline of ocular disease therapies has great potential to become innovative and convenient treatment options for patients suffering from glaucoma and other eye disorders,” said Mr. Machado. “I look forward to providing strategic guidance to the Inotek team during this critical stage of *trabodenoson*’s development.”

#### **About Inotek Pharmaceuticals Corporation**

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, *trabodenoson*, is a first-in-class selective adenosine mimetic currently in Phase 3 development. *Trabodenoson* was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit [www.inotekpharma.com](http://www.inotekpharma.com). The inclusion of our website address here and elsewhere in this press release does not include or incorporate by reference the information on our website into this press release.



### **Forward-Looking Statements**

This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

### **Inotek Contact:**

Claudine Prowse, PhD, 781-552-4305  
Vice President, Strategy and Investor Relations Officer  
IR@inotekpharma.com

### **Investor Contact:**

MacDougall Biomedical Communications  
Chris Erdman, 781-235-3060  
cerdman@macbiocom.com

### **Media Contact:**

MacDougall Biomedical Communications  
Karen Sharma, 781-235-3060  
ksharma@macbiocom.com